A new drug for weight-loss has won approval from the U.S. Food and Drug Administration. Philly.com reports that the agency gave the go-ahead to the use of Contrave for overweight and obese people.
“Contrave is a combination of two already-approved drugs, naltrexone and bupropion, in extended-release form. The former is approved to treat alcohol or opioid dependence, while the latter is approved for depression, seasonal affective disorder and as a smoking-cessation aid,” the story reports.
The FDA said in a press release that the approval is for use by people with a body-mass index of 30 or more, which is considered obese.
“It also is sanctioned for people with a BMI of 27 or higher, which is considered overweight, who also have at least one weight-related chronic health condition. Such a condition would include high blood pressure, high cholesterol or type 2 diabetes,” the report adds.
The FDA indicated that more than one-third of U.S. adults are obese.
“Contrave was evaluated in clinical trials involving some 4,500 obese and overweight people. Results showed people who took Contrave had an average weight loss of 4.1 percent more than people given a placebo,” the story reports.